| ROLLIG, C., B. STEFFEN, N. ALAKEL, R. HERBST, R. NOPPENEY, M. HANOUN, Z. RACIL, K. SCHAFER-ECKART, A. KRAMER, A. NEUBAUER, C. D. BALDUS, C. SCHLIEMANN, M. KAUFMANN, J. MERTOVA, E. JOST, D. NIEMANN, J. NOVAK, S. W. KRAUSE, S. SCHOLL, G. HELD, S. B. PARMENTIER, T. SZOTKOWSKI, P. ZAK, A. RANK, M. WASS, S. BUSKE, M. KRAMER, F. FIEBIG, A. HAAKE, J. SCHETELIG, U. PLATZBECKER, C. THIEDE, C. MULLER-TIDOW, W. E. BERDEL, H. SERVE, G. EHNINGER, Jiří MAYER and M. BORNHAUSER. Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial. 2020. Available from: https://dx.doi.org/10.1182/blood-2020-140246. |
Other formats:
BibTeX
LaTeX
RIS
@proceedings{1807008,
author = {Rollig, C. and Steffen, B. and Alakel, N. and Herbst, R. and Noppeney, R. and Hanoun, M. and Racil, Z. and SchaferandEckart, K. and Kramer, A. and Neubauer, A. and Baldus, C. D. and Schliemann, C. and Kaufmann, M. and Mertova, J. and Jost, E. and Niemann, D. and Novak, J. and Krause, S. W. and Scholl, S. and Held, G. and Parmentier, S. B. and Szotkowski, T. and Zak, P. and Rank, A. and Wass, M. and Buske, S. and Kramer, M. and Fiebig, F. and Haake, A. and Schetelig, J. and Platzbecker, U. and Thiede, C. and MullerandTidow, C. and Berdel, W. E. and Serve, H. and Ehninger, G. and Mayer, Jiří and Bornhauser, M.},
doi = {http://dx.doi.org/10.1182/blood-2020-140246},
keywords = {Daunodouble; clinical trial; Acute myeloid leukemia; cytarabine; anthracycline},
language = {eng},
title = {Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial},
url = {https://ashpublications.org/blood/article/136/Supplement%201/1/470174/Remission-and-Survival-after-Single-Versus-Double},
year = {2020}
}
TY - CONF
ID - 1807008
AU - Rollig, C. - Steffen, B. - Alakel, N. - Herbst, R. - Noppeney, R. - Hanoun, M. - Racil, Z. - Schafer-Eckart, K. - Kramer, A. - Neubauer, A. - Baldus, C. D. - Schliemann, C. - Kaufmann, M. - Mertova, J. - Jost, E. - Niemann, D. - Novak, J. - Krause, S. W. - Scholl, S. - Held, G. - Parmentier, S. B. - Szotkowski, T. - Zak, P. - Rank, A. - Wass, M. - Buske, S. - Kramer, M. - Fiebig, F. - Haake, A. - Schetelig, J. - Platzbecker, U. - Thiede, C. - Muller-Tidow, C. - Berdel, W. E. - Serve, H. - Ehninger, G. - Mayer, Jiří - Bornhauser, M.
PY - 2020
TI - Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial
KW - Daunodouble
KW - clinical trial
KW - Acute myeloid leukemia
KW - cytarabine
KW - anthracycline
UR - https://ashpublications.org/blood/article/136/Supplement%201/1/470174/Remission-and-Survival-after-Single-Versus-Double
N2 - Double induction using two subsequent 7+3 regimens of cytarabine plus anthracycline is commonly performed in AML patients with an adequate performance status in order to maximize dose intensity upfront. However, for patients with a good early response at day 15 of first induction, there is no prospective randomized evidence on the necessity or value of a second induction cycle. In order to answer the question if good responders of the first 7+3 induction could be spared a second induction cycle, we set up randomized-controlled SAL DaunoDouble trial. The study prospectively assesses the outcome of patients with a good early response with respect to the number of induction cycles (single versus double). We assumed non-inferiority of single induction in terms of complete remission (CR/CRi) rate, based on a margin of 7.5%. Here, we present the results of the planned interim analysis.
ER -
ROLLIG, C., B. STEFFEN, N. ALAKEL, R. HERBST, R. NOPPENEY, M. HANOUN, Z. RACIL, K. SCHAFER-ECKART, A. KRAMER, A. NEUBAUER, C. D. BALDUS, C. SCHLIEMANN, M. KAUFMANN, J. MERTOVA, E. JOST, D. NIEMANN, J. NOVAK, S. W. KRAUSE, S. SCHOLL, G. HELD, S. B. PARMENTIER, T. SZOTKOWSKI, P. ZAK, A. RANK, M. WASS, S. BUSKE, M. KRAMER, F. FIEBIG, A. HAAKE, J. SCHETELIG, U. PLATZBECKER, C. THIEDE, C. MULLER-TIDOW, W. E. BERDEL, H. SERVE, G. EHNINGER, Jiří MAYER and M. BORNHAUSER. \textit{Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial}. 2020. Available from: https://dx.doi.org/10.1182/blood-2020-140246.
|
